Charles Schwab Investment Management Inc Gemini Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.73 $56,672 - $80,363	-46,453 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.29 - $3.08 $14,555 - $34,751	-11,283 Reduced 19.54%	46,453 $65,000
Q3 2021 Nov 16, 2021	SELL	$3.3 - $6.32 $426,977 - $817,725	-129,387 Reduced 69.15%	57,736 $234,000
Q2 2021 Aug 16, 2021	BUY	$6.32 - $14.02 $273,472 - $606,659	43,271 Added 30.08%	187,123 $1.21 Million
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $1.63 Million - $2.59 Million	143,852 New	143,852 $1.95 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.